ANL

Adlai Nortye Group Ltd. - American Depositary Shares (ANL)

About Adlai Nortye Group Ltd. - American Depositary Shares (ANL)

Adlai Nortye Group Ltd. is a clinical-stage biopharmaceutical company, which engages in the provision of development of cancer therapies for patients with stages of tumors. It offers AN0025, a clinical stage, potential EP4 antagonist designed to modulate tumor microenvironment. The company was founded on May 9, 2018, and is headquartered in Hangzhou, China.

Details

Daily high

$9.85

Daily low

$8.90

Price at open

$9.61

52 Week High

$17.25

52 Week Low

$0.88

Market cap

564.4M

Dividend yield

Volume

450,321

Avg. volume

350,127

P/E ratio

-17.70

Adlai Nortye Group Ltd. - American Depositary Shares News